Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Andhra Pradesh, India.
Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Andhra Pradesh, India.
Indian J Pharmacol. 2019 Sep-Oct;51(5):330-336. doi: 10.4103/ijp.IJP_217_18. Epub 2019 Nov 26.
Chronic kidney failure among people with diabetes mellitus (DM) is a burgeoning health problem that affects up to 25% of patients with type 2 DM. Current pharmacological treatment for diabetic nephropathy (DN) does not stop the attainment of renal complications. The intention of the current study was to explore the role of a polyherbal formulation (PHF) in diabetic-induced nephropathy in experimental animals.
Diabetic rats were grouped as follows and underwent the following treatment for about 16 weeks: Group I - normal rats - no treatment, Group II - DN rats - only vehicle (p.o), and Group III and IV - DN rats - PHF orally at 250 and 500 mg/kg, respectively. After the treatment, the animals were sacrificed, and lipid, renal function, and inflammatory markers were estimated. The observed microscopic changes in kidney were analyzed.
Animals administered with PHF exhibited noteworthy decrease in triglycerides, total cholesterol, very low-density lipoprotein (LDL), LDL, serum creatinine, urinary protein, urinary albumin excretion rate, advanced glycation end products, type IV collagen excretion, interleukin-6, transforming growth factor-ß, and tumor necrosis factor-alpha and showed significant increase in high-density lipoprotein, urine volume, urinary urea, and urine creatinine. Histopathological examination established that administration of PHF prohibited kidney damage.
Treatment with PHF showed beneficial effect on DN which may be due to the improvement of renal function parameters and hyperlipidemic and inflammatory mediators.
糖尿病患者的慢性肾衰竭是一个日益严重的健康问题,影响多达 25%的 2 型糖尿病患者。目前治疗糖尿病肾病(DN)的药物并不能阻止肾脏并发症的发生。本研究旨在探讨一种复方草药制剂(PHF)在实验动物糖尿病诱导的肾病中的作用。
糖尿病大鼠分为以下几组,并接受了大约 16 周的治疗:I 组 - 正常大鼠 - 不治疗;II 组 - DN 大鼠 - 仅给予载体(口服);III 组和 IV 组 - DN 大鼠 - 分别给予 PHF 250 和 500mg/kg 口服。治疗后,处死动物,评估脂质、肾功能和炎症标志物。分析肾脏的微观变化。
给予 PHF 的动物表现出显著降低三酰甘油、总胆固醇、极低密度脂蛋白(LDL)、LDL、血清肌酐、尿蛋白、尿白蛋白排泄率、晚期糖基化终产物、IV 型胶原排泄、白细胞介素-6、转化生长因子-β和肿瘤坏死因子-α,并显著增加高密度脂蛋白、尿量、尿尿素和尿肌酐。组织病理学检查证实,PHF 的给药可防止肾脏损伤。
PHF 治疗 DN 具有有益的效果,这可能是由于改善了肾功能参数以及血脂和炎症介质。